Your session is about to expire
← Back to Search
Nivolumab + Ipilimumab + Embolization for Renal Cell Carcinoma
Study Summary
This trial will study the safety of combining nivolumab+ipilimumab with embolization in patients with metastatic renal cell carcinoma.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is admission to this trial available at the moment?
"The current status of the clinical trial is recruiting, according to information provided on clinicaltrials.gov. It was initially announced on August 26th 2020 and subsequently updated most recently in March 14th 2022."
To what degree could bland embolization pose a hazard to patients?
"Due to the limited data collected in Phase 1 trials, our team at Power rated bland embolization safety a score of 1."
What is the aggregate participant count of this healthcare experiment?
"Affirmative. According to clinicaltrials.gov, this trial is in the process of recruiting participants with an initial posting on August 26th 2020 and a recently updated version posted on March 14th 2022. 22 individuals are sought from 1 particular facility."
What health conditions does bland embolization typically address?
"Bland embolization is frequently deployed to address the effects of anti-angiogenic therapy. In addition, it can be used to treat certain malignant neoplasms, melanomas that are inoperable and squamous cell carcinoma."
What other research endeavors have focused on bland embolization?
"Presently, 86 Phase 3 trials for bland embolization are ongoing and 764 of these clinical studies remain active. Although the majority of them originate from Pittsburgh, Pennsylvania, a total of 42760 sites offer this type of medical research."
Share this study with friends
Copy Link
Messenger